

INDINDAT	– 16 <sup>th</sup> April 2018			
09:00	Registration open for CEP and Congress Delegates – <i>Gateshead Foyer</i>			
	Continuing Education Programme			
	Hillgate			
	Immuno-oncology – safety asses	ssment strategies		
	Chair: Simon Chivers (ADC Th	nerapeutics)		
10:00 – 10:45	IO therapies – safety assessment strategies for therapeutic antibodies			
	Dr Lolke de Haan (MedImmune, UK)  CD3 engagers and CART cell therapies and the challenges / issues with safety assessment			
10:45 – 11:30	Jennifer Sims (Integrated Biologix, UK)			
11:30 – 12:00	Refreshments – Gateshead Foyer			
12:00 – 12:45	Animal models in oncology efficacy and safety testing  Silvia Guionaud (AstraZeneca, UK)	Animal models in oncology efficacy and safety testing  Silvia Guionaud (AstraZeneca, LIK)		
12:45 – 13.30	Lunch and Trade Exhibition – <b>Gateshead Foyer</b>	·		
	Congress Progra	mme		
13:30 - 13:45	Pipewellgate/Oakwellgate			
	Welcome by the BTS President Dr Er	Welcome by the BTS President Dr Ernie Harpur (Newcastle University, UK)		
	Pipewellgate/Oakwellgate			
	1	Lecture:		
13:45 – 14:45	· ·	Collaboration, Communication & Caution		
	Ms Syril Pettit (ILSI Health and Environmental Sciences Institute, Washington DC, USA)  Chair: Dr Ernie Harpur (Newcastle University, UK)			
	Chair. Di Etille Harpar (1	Newcastie Officersity, OK)		
	Pipewellgate/Oakwellgate	Hillgate		
	Symposium 1:	Symposium 2:		
	Liver disease and environmental causes of liver disease	Respiratory toxicity and lung pathology (BTS/BSTP session)		
	Chairs: Sarah Judge (University of Newcastle, UK)	Chairs: Dr Jo Kilgour (Regulatory Science Associates, Uk		
	Dr Dominic Williams (AstraZeneca, UK)	Dr Catherine Ross (Covance UK)		
	1			
		Responses of the respiratory tract to toxic injury:		
14:45 – 15:15	Introduction to liver disease	adverse vs non adverse findings and impact on drug		
14:45 – 15:15	Introduction to liver disease  Professor Fiona Oakley (University of Newcastle, UK)			
14:45 – 15:15	Professor Fiona Oakley (University of Newcastle, UK)	adverse vs non adverse findings and impact on drug development  Dr Colin Fish (GSK, UK)		
14:45 – 15:15 15:15 – 15:45		adverse vs non adverse findings and impact on drug development		
15:15 – 15:45	Professor Fiona Oakley (University of Newcastle, UK)  Hepatic responses to injury in liver disease  Dr Patricia Lalor (University of Birmingham, UK)	adverse vs non adverse findings and impact on drug development  Dr Colin Fish (GSK, UK)  Nanoparticle Toxicology		
	Professor Fiona Oakley (University of Newcastle, UK)  Hepatic responses to injury in liver disease Dr Patricia Lalor (University of Birmingham, UK)  Refreshments and Trade Exhibition – Gateshead Foyer	adverse vs non adverse findings and impact on drug development  Dr Colin Fish (GSK, UK)  Nanoparticle Toxicology  Dr Rodger Duffin (Edinburgh University, UK)		
15:15 – 15:45	Professor Fiona Oakley (University of Newcastle, UK)  Hepatic responses to injury in liver disease Dr Patricia Lalor (University of Birmingham, UK)  Refreshments and Trade Exhibition – Gateshead Foyer  Immunological mechanisms underlying drug-induced liver diseases	adverse vs non adverse findings and impact on drug development  Dr Colin Fish (GSK, UK)  Nanoparticle Toxicology  Dr Rodger Duffin (Edinburgh University, UK)  Air Pollution and Public Health: emerging hazards and improved understanding of risk		
15:15 – 15:45 15:45 – 16:15	Professor Fiona Oakley (University of Newcastle, UK)  Hepatic responses to injury in liver disease Dr Patricia Lalor (University of Birmingham, UK)  Refreshments and Trade Exhibition – Gateshead Foyer  Immunological mechanisms underlying drug-induced	adverse vs non adverse findings and impact on drug development  Dr Colin Fish (GSK, UK)  Nanoparticle Toxicology  Dr Rodger Duffin (Edinburgh University, UK)  Air Pollution and Public Health: emerging hazards and		
15:15 – 15:45 15:45 – 16:15	Professor Fiona Oakley (University of Newcastle, UK)  Hepatic responses to injury in liver disease Dr Patricia Lalor (University of Birmingham, UK)  Refreshments and Trade Exhibition – Gateshead Foyer  Immunological mechanisms underlying drug-induced liver diseases	adverse vs non adverse findings and impact on drug development  Dr Colin Fish (GSK, UK)  Nanoparticle Toxicology  Dr Rodger Duffin (Edinburgh University, UK)  Air Pollution and Public Health: emerging hazards and improved understanding of risk		
15:15 – 15:45 15:45 – 16:15	Professor Fiona Oakley (University of Newcastle, UK)  Hepatic responses to injury in liver disease Dr Patricia Lalor (University of Birmingham, UK)  Refreshments and Trade Exhibition – Gateshead Foyer  Immunological mechanisms underlying drug-induced liver diseases Professor Guru Aithal (University of Nottingham, UK)  Looking for toxins in the environment that could be associated with a trigger for the liver disease PBC	adverse vs non adverse findings and impact on drug development  Dr Colin Fish (GSK, UK)  Nanoparticle Toxicology Dr Rodger Duffin (Edinburgh University, UK)  Air Pollution and Public Health: emerging hazards and improved understanding of risk  Professor Frank Kelly (Kings College London, UK)  Optical Molecular Sensing and Imaging of Human Disease In Situ		
15:15 - 15:45 15:45 - 16:15 16:15 - 16:45 16:45 - 17:15	Professor Fiona Oakley (University of Newcastle, UK)  Hepatic responses to injury in liver disease Dr Patricia Lalor (University of Birmingham, UK)  Refreshments and Trade Exhibition – Gateshead Foyer  Immunological mechanisms underlying drug-induced liver diseases Professor Guru Aithal (University of Nottingham, UK)  Looking for toxins in the environment that could be associated with a trigger for the liver disease PBC Professor Matt Wright (University of Newcastle, UK)	adverse vs non adverse findings and impact on drug development  Dr Colin Fish (GSK, UK)  Nanoparticle Toxicology Dr Rodger Duffin (Edinburgh University, UK)  Air Pollution and Public Health: emerging hazards and improved understanding of risk  Professor Frank Kelly (Kings College London, UK)  Optical Molecular Sensing and Imaging of Human		
15:15 - 15:45 15:45 - 16:15 16:15 - 16:45 16:45 - 17:15	Professor Fiona Oakley (University of Newcastle, UK)  Hepatic responses to injury in liver disease Dr Patricia Lalor (University of Birmingham, UK)  Refreshments and Trade Exhibition – Gateshead Foyer  Immunological mechanisms underlying drug-induced liver diseases Professor Guru Aithal (University of Nottingham, UK)  Looking for toxins in the environment that could be associated with a trigger for the liver disease PBC Professor Matt Wright (University of Newcastle, UK)  BTS AGM – Pipewellgate/Oakwellgate	adverse vs non adverse findings and impact on drug development  Dr Colin Fish (GSK, UK)  Nanoparticle Toxicology Dr Rodger Duffin (Edinburgh University, UK)  Air Pollution and Public Health: emerging hazards and improved understanding of risk  Professor Frank Kelly (Kings College London, UK)  Optical Molecular Sensing and Imaging of Human Disease In Situ  Dr Kev Dhaliwal (EPSRC Proteus Group, UK)		
15:15 - 15:45 15:45 - 16:15 16:15 - 16:45 16:45 - 17:15	Professor Fiona Oakley (University of Newcastle, UK)  Hepatic responses to injury in liver disease Dr Patricia Lalor (University of Birmingham, UK)  Refreshments and Trade Exhibition – Gateshead Foyer  Immunological mechanisms underlying drug-induced liver diseases Professor Guru Aithal (University of Nottingham, UK)  Looking for toxins in the environment that could be associated with a trigger for the liver disease PBC Professor Matt Wright (University of Newcastle, UK)  BTS AGM – Pipewellgate/Oakwellgate Drinks Reception with canapés and poster viewing supplements.	adverse vs non adverse findings and impact on drug development  Dr Colin Fish (GSK, UK)  Nanoparticle Toxicology Dr Rodger Duffin (Edinburgh University, UK)  Air Pollution and Public Health: emerging hazards and improved understanding of risk  Professor Frank Kelly (Kings College London, UK)  Optical Molecular Sensing and Imaging of Human Disease In Situ  Dr Kev Dhaliwal (EPSRC Proteus Group, UK)		
15:15 - 15:45 15:45 - 16:15 16:15 - 16:45 16:45 - 17:15	Professor Fiona Oakley (University of Newcastle, UK)  Hepatic responses to injury in liver disease Dr Patricia Lalor (University of Birmingham, UK)  Refreshments and Trade Exhibition – Gateshead Foyer  Immunological mechanisms underlying drug-induced liver diseases Professor Guru Aithal (University of Nottingham, UK)  Looking for toxins in the environment that could be associated with a trigger for the liver disease PBC Professor Matt Wright (University of Newcastle, UK)  BTS AGM – Pipewellgate/Oakwellgate	adverse vs non adverse findings and impact on drug development  Dr Colin Fish (GSK, UK)  Nanoparticle Toxicology Dr Rodger Duffin (Edinburgh University, UK)  Air Pollution and Public Health: emerging hazards and improved understanding of risk  Professor Frank Kelly (Kings College London, UK)  Optical Molecular Sensing and Imaging of Human Disease In Situ  Dr Kev Dhaliwal (EPSRC Proteus Group, UK)		



TUESDAY – 17 <sup>th</sup> April 2018				
08:00	Registration opens - <i>Gateshead Foyer</i>			
08:00 - 08:40	BTS Ambassadors Breakfast			
08:40 – 09:25	Pipewellgate/Oakwellgate  Early Career Investigator Prize Lecture: Role of Nrf2 in protection against drug-induced disease  Dr Ian Copple (University of Liverpool)  Chair: Professor Tim Gant (Public Health England Centre for Radiation, Chemical and Environmental Hazards,			
	Pipewellgate/Oakwellgate  Symposium 3:  Advanced in vitro models for inhalation toxicity testing (BTS/IVTS session)  Chair: Dr Martin Clift (Swansea University Medical School, UK)	Hillgate  Symposium 4:  Ageing, Frailty and Multi-morbidity: medical challenges, current interventions, future solutions Co- Sponsored by the Regulatory Toxicology Speciality Section and the Human Toxicology Speciality Section  Chairs: Dr Henry Stemplewski (Medicines and Healthcare products Regulatory Agency, UK)  Dr John Thompson (Cardiff University, UK)		
09:30 – 10:00	In vitro systems to study the toxicology of particles and drugs at the epithelial lung tissue barrier  Professor Barbara Rothen-Rutishauser (Adolphe Merkle Institute, University of Fribourg, Switzerland)	Ageing and Frailty: time to intervene  Professor Thomas von Zglinicki (University of Newcastle, UK)		
10:00 – 10:30	Synthetic lung lining fluid model for testing inhaled pharmaceuticals <b>Dr Ben Forbes</b> (King's College London, UK)	Assessment of ageing in preclinical models: current and future models and their clinical relevance  Professor Susan Howlett (Department of Pharmacology, Division of Geriatric Medicine Halifax, Nova Scotia, Canada)		
10:30 – 11:00	Refreshments and Trade Exhibition – <b>Gateshead Foyer</b>			
11:00 – 11:30	Complex organ-on-chip technology meets routine laboratory work. A breathing human alveolus-on-chip model for in-vitro drug transport and safety studies.  Dr Nina Hobi (Alveolix, Switzerland)	Biomarkers of ageing: the results from the EU FP7 MARK-AGE project Dr Andreas Simm (University Hospital Halle [Saale], Germany)		
11:30 – 12:00	Use of air-liquid interface models in the pharma space  Mrs Kinga Balogh Sivars (AstraZeneca, Sweden)	Ageing, Frailty, Multi-morbidity: current medical interventions, future challenges, possible solutions  Professor Ilaria Bellantuono (University of Sheffield Medical School, UK)		
12:00 – 12:30	How to get published  Rebecca Brodie (Deputy Editor, Toxicology Research)  Chair: Professor Tim Gant (PHE & University of Surrey, UK)			
12:30 – 13:30	Lunch and Trade Exhibition – <b>Gateshead Foyer</b>			
13:30 – 14:30	Pipewellgate/Oakwellgate  Paton Prize Lecture:  The Importance of Balance in Toxicological Decision Making  Professor Lewis Smith (University of Leicester, UK)  Chair: Dr Ernie Harpur (Newcastle University, UK)			
14:30 – 15:00	Refreshments and Trade Exhibition – <b>Gateshead Foyer</b>			
17.50 15.00	Action and Trade Exhibition - Gatesiieau Poyer			

TUESDAY – 17 <sup>th</sup> April 2018 (Cont'd)				
	Pipewellgate/Oakwellgate	Hillgate		
15:00 – 17:00	Oral Communications Chairs: Dr Dominic Williams (Imperial College London, UK) Dr Patricia Parris (AstraZeneca, UK)  • Alistair Leitch: Evidence that CYP3A4 metabolises the ionic liquid M8OI • Arathi Kizhedath: Assessment of hepatotoxic and dermal toxicity effects of Parabens using HepG2 and HDFN in vitro models • Ben Alexander-Dann: Understanding cellular infiltrate toxicity in liver using gene co-expression network methods • Kirsty Meldrum: Cerium dioxide nanoparticles modify the pulmonary response to diesel exhaust particles in a murine model of allergen exposure • Kayleigh Frame: Understanding the Galactose-conditioning Model in HepG2 cells: Beyond bioenergetics reveals additional mechanisms of mitochondrial toxicity • Israa Al-banaa: Neurotoxicological analysis of synthetic cannabinoids using human neuronal stem cells • Dr Emma Marczylo: Using next generation sequencing to study the environmental mycobiome and its potential health effects • Alex Charlton: The use of a 3D in vitro model of the respiratory tract for risk assessment of an irritant aerosol	Study Director/Study Monitor Workshop Chairs: Sean O'Halloran (Covance, UK) Graham Morgan (ICON, UK)  • Use of Recovery Dose Animals in Early Toxicology Testing Dr Paul Baldrick (Covance Laboratories Ltd, UK)  • Can Study Directors perform miracles!!! Lorraine Britton (Sequani Ltd, UK)  • Fundamental considerations for performing a rodent inhalation toxicology study with a pharmaceutical powder formulation Paul A Smith (Charles River Laboratories, UK)  • The current status of the GLP/ global GLP debate ongoing with the OECD and Chinese governments David Jones (MHRA, UK)		
17:00 – 18:30	Poster Session – Gateshead Foyer			
19:00 – 19:30	Pre-Dinner Drinks Reception supported by ApconiX – Gateshead Foyer			
19:30 – Late	Congress Dinner & Entertainment by Gotcha! – Gateshead Suite			



WEDNESDAY – 18 <sup>th</sup> April 2018				
08:00	Registration opens – Gateshead Foyer			
	Pipewellgate/Oakwellgate			
	Oral Presentations Chair: Dr Tina Mehta (Dow Agrosciences, UK)			
08:40 - 09:40	<ul> <li>Dr Ivano Amelio: The p53 family in the response to hypoxic stress</li> <li>Dr Ross Kelly: Thermodynamic-based in silico simulations of quinone redox cycling pred induced mitochondrial oxidative stress</li> <li>Dr Liza Selley: Non-invasively accessible miRNA biomarkers of pulmonary inflammatory vivo</li> </ul>			
	Pipewellgate/Oakwellgate	Hillgate		
	Symposium 5: Redox and oxidative stress	Symposium 6: Stem cells and toxicology testing (BTS/RSC session)		
	Chairs: Professor Tim Gant (PHE & University of Surrey, UK) Dr Carol Courage (Walgreens Boots Alliance, UK)	<b>Chairs</b> : Professor Marion MacFarlane (MRC Toxicology Unit, UK)  Dr Muireann Coen (AstraZeneca, UK)		
09:45 – 10:15	Mitochondria and Redox Stress: A Biomarker for Toxicology Professor Victor Darley Usmar (University of Alabama, USA)	Advances in stem cell technologies: impact on toxicology <b>Dr Jason Gill</b> (Newcastle University, UK)		
10:15 – 10:45	NRF 2 and antioxidant response  Professor John Hayes (University of Dundee, UK)	A human ES cell-based platform for determining selective neurotoxicity <b>Dr Lia Panman</b> (MRC Toxicology Unit, UK)		
10:45 – 11:15	Refreshments and Trade Exhibition – <b>Gateshead Foyer</b>			
11:15 – 11:45	Biomarkers of oxidative stress  Professor Pietro Ghezzi (Brighton and Sussex  Medical School, UK)	High-throughput human Organ-on-a-Chip models for prediction of neurotoxicity <b>Dr Karlijn Wilschut</b> (Mimetas, University of Utrecht, The Netherlands)		
11:45 – 12:15	Redox and cellular stress in relation to consumer risk assessments  Dr Alistair Middleton (Unilever, UK)	Screening models to improve decision making in drug development: Validation or Qualification? <b>Dr Mark Holbrook</b> (VAST Pharma Solutions, UK)		
12:15 – 13:00	Lunch and Trade Exhibition – <b>Gateshead Foyer</b>			
	Pipewellgate/Oakwellgate			
13:00 – 14:00	Hot Topic Lecture: Challenges in the Assessment of Nonclinical Pharmacology and Safety of mAb-based Imm Oncology Products Dr Lolke de Haan (MedImmune, UK) Chair: Dr Peter Newham (AstraZeneca, UK)			
	Pipewellgate/Oakwellgate			
14:00 – 15:00	Public Communications Workshop: Consultation on a BTS public communication initiative; an interactive workshop.  Chairs: Phil Botham (Syngenta, UK) and Chris Powell (GSK, UK)			
15:00	Close of Congress			
	, ,			